Target Name: SNX7
NCBI ID: G51375
Review Report on SNX7 Target / Biomarker Content of Review Report on SNX7 Target / Biomarker
SNX7
Other Name(s): Sorting nexin 7, transcript variant 1 | MGC8717 | Sorting nexin-7 (isoform a) | Sorting nexin-7 | SNX7_HUMAN | DKFZp564F052 | sorting nexin 7 | Sorting nexin 7 | SNX7 variant 1

SNX7: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, over 21,000 women will be diagnosed with ovarian cancer in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 40%. The discovery of potential drug targets and biomarkers for ovarian cancer could lead to new, more effective treatments. One such potential drug target is SNX7, a protein that has been identified as a potential biomarker and drug target for ovarian cancer.

SNX7 is a nuclear transmembrane protein that is expressed in a variety of tissues, including the ovaries, brain, and heart. It is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in the development and progression of ovarian cancer. Several studies have suggested that SNX7 may be a potential drug target for ovarian cancer, due to its involvement in cell growth and survival factors.

One of the key features of SNX7 is its role in the regulation of the PI3K/Akt signaling pathway. This signaling pathway is involved in the regulation of cell growth, differentiation, and survival, and is a target for many anti-cancer drugs. SNX7 has been shown to play a role in the regulation of PI3K/Akt signaling pathway in ovarian cancer cells, and may be a potential drug target for this disease.

Another potential mechanism by which SNX7 may be involved in the development of ovarian cancer is its role in the regulation of the NF-kappa-B signaling pathway. This signaling pathway is involved in the regulation of inflammation and immune responses, and has been implicated in the development of ovarian cancer. SNX7 has been shown to play a role in the regulation of NF-kappa-B signaling pathway in ovarian cancer cells, and may be a potential drug target for this disease.

In addition to its potential role in cell growth and survival factors, SNX7 has also been shown to play a role in the regulation of the Wnt signaling pathway. This signaling pathway is involved in the regulation of cell growth and development, and has been implicated in the development of ovarian cancer. SNX7 has been shown to play a role in the regulation of Wnt signaling pathway in ovarian cancer cells, and may be a potential drug target for this disease.

The identification of potential drug targets and biomarkers for ovarian cancer is an important step in the development of new treatments for this disease. SNX7, with its involvement in cell growth and survival factors, NF-kappa-B signaling pathway, and Wnt signaling pathway, is a potential drug target and biomarker for ovarian cancer. Further research is needed to determine the effectiveness of SNX7 as a drug target and biomarker for ovarian cancer.

In conclusion, SNX7 is a protein that has been identified as a potential drug target and biomarker for ovarian cancer. Its involvement in cell growth and survival factors, NF-kappa-B signaling pathway, and Wnt signaling pathway make it a promising target for the development of new treatments for ovarian cancer. Further research is needed to determine the effectiveness of SNX7 as a drug target and biomarker for ovarian cancer.

Protein Name: Sorting Nexin 7

Functions: Involved in the regulation of endocytosis and in several stages of intracellular trafficking (PubMed:32513819). Together with SNX4, involved in autophagosome assembly by regulating trafficking and recycling of phospholipid scramblase ATG9A (PubMed:32513819)

The "SNX7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140 | SP140L | SP2 | SP2-AS1 | SP3 | SP3P | SP4 | SP5 | SP6 | SP7 | SP8 | SP9 | SPA17 | SPAAR | SPACA1 | SPACA3 | SPACA4